119- Gonzalez AA, Green T, Luffman C, Bourgeois CR, Gabriel Navar L, Prieto MC. Renal med-
ullary cyclooxygenase-2 and (pro)renin receptor expression during angiotensin II-dependent
hypertension. Am J Physiol Ren Physiol. 2014;307(8):F962–70. - Wang F, Lu X, Peng K, Du Y, Zhou SF, Zhang A, et al. Prostaglandin E-prostanoid4 recep-
tor mediates angiotensin II-induced (pro)renin receptor expression in the rat renal medulla.
Hypertension. 2014;64(2):369–77. - Gonzalez AA, Prieto MC. Renin and the (pro)renin receptor in the renal collecting duct: role
in the pathogenesis of hypertension. Clin Exp Pharmacol Physiol. 2015;42(1):14–21. - Li W, Peng H, Mehaffey EP, Kimball CD, Grobe JL, van Gool JM, et al. Neuron-specific
(pro)renin receptor knockout prevents the development of salt-sensitive hypertension.
Hypertension. 2014;63(2):316–23. - Bracquart D, Cousin C, Contrepas A, Nguyen G. The prorenin receptor. J Soc Biol.
2009;203(4):303–10. - Utsunomiya H, Nakamura M, Kakudo K, Inagami T, Tamura M. Angiotensin II AT2 receptor
localization in cardiovascular tissues by its antibody developed in AT2 gene-deleted mice.
Regul Pept. 2005;126(3):155–61. - Hsieh PS, Tai YH, Loh CH, Shih KC, Cheng WT, Chu CH. Functional interaction of AT1
and AT2 receptors in fructose-induced insulin resistance and hypertension in rats. Metab Clin
Exp. 2005;54(2):157–64. - Strehlow K, Nickenig G, Roeling J, Wassmann S, Zolk O, Knorr A, et al. AT(1) receptor
regulation in salt-sensitive hypertension. Am J Phys. 1999;277(5 Pt 2):H1701–7. - Harrison-Bernard LM, Schulman IH, Raij L. Postovariectomy hypertension is linked to
increased renal AT1 receptor and salt sensitivity. Hypertension. 2003;42(6):1157–63. - Szombathy T, Szalai C, Katalin B, Palicz T, Romics L, Csaszar A. Association of angiotensin
II type 1 receptor polymorphism with resistant essential hypertension. Clinica Chimica Acta
Int J Clin Chem. 1998;269(1):91–100. - Hunyady L, Turu G. The role of the AT1 angiotensin receptor in cardiac hypertrophy: angio-
tensin II receptor or stretch sensor? Trends Endocrinol Metab TEM. 2004;15(9):405–8. - Liao Y, Husain A. The chymase-angiotensin system in humans: biochemistry, molecular biol-
ogy and potential role in cardiovascular diseases. Can J Cardiol. 1995;11(Suppl F):13f–9f. - Mangiapane ML, Rauch AL, MacAndrew JT, Ellery SS, Hoover KW, Knight DR, et al.
Vasoconstrictor action of angiotensin I-convertase and the synthetic substrate (Pro11,D-
Ala12)-angiotensin I. Hypertension. 1994;23(6 Pt 2):857–60. - Nagata S, Varagic J, Kon ND, Wang H, Groban L, Simington SW, et al. Differential expres-
sion of the angiotensin-(1-12)/chymase axis in human atrial tissue. Ther Adv Cardiovasc Dis.
2015;9(4):168–80. - Park S, Bivona BJ, Ford SM Jr, Xu S, Kobori H, de Garavilla L, et al. Direct evidence for
intrarenal chymase-dependent angiotensin II formation on the diabetic renal microvascula-
ture. Hypertension. 2013;61(2):465–71. - Leckie BJ. Targeting the renin-angiotensin system: what’s new? Curr Med Chem Cardiovasc
Hematol Agents. 2005;3(1):23–32. - Leung PS. The peptide hormone angiotensin II: its new functions in tissues and organs. Curr
Protein Pept Sci. 2004;5(4):267–73. - Re RN. The clinical implication of tissue renin angiotensin systems. Curr Opin Cardiol.
2001;16(6):317–27. - Zhuo JL, Li XC. New insights and perspectives on intrarenal renin-angiotensin system: focus
on intracrine/intracellular angiotensin II. Peptides. 2011;32(7):1551–65. - Kumar R, Thomas CM, Yong QC, Chen W, Baker KM. The intracrine renin-angiotensin sys-
tem. Clin Sci (London, England: 1979). 2012;123(5):273–84. - Re RN. Intracellular renin and the nature of intracrine enzymes. Hypertension.
2003;42(2):117–22. - De Mello WC, Danser AH. Angiotensin II and the heart : on the intracrine renin-angiotensin
system. Hypertension. 2000;35(6):1183–8.
7 Pathophysiological Insights in Resistant Hypertension